14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026
AVDL vs ANIP: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 20, 2026, Avadel Pharmaceuticals plc Ordinary Share (AVDL) captures the overall head-to-head institutional edge over ANI Pharmaceuticals, Inc. (ANIP) on higher Unified Composite conviction (62.9/100 BUY vs. 42.4/100 HOLD) after splitting the core matrix 5–5 (led by Growth & Scale), while ANIP wins 5–1 across the 6-pillar growth and valuation breakdown. AVDL trades at $21.64 (28.8x Forward P/E, 2.5% operating margin) versus ANIP at $68.55 (6.7x Forward P/E, 14.7% operating margin).
Growth vs. Quality Trade-Off: AVDL earns the overall head-to-head edge with a stronger Unified Composite Score (62.9/100 BUY vs. ANIP 42.4/100 HOLD) and 0.14β · 2% Vol risk profile, whereas ANIP leads top-line expansion (+27.6% YoY revenue growth, 1.76x PEG, and 5 of 6 institutional pillars) for higher-beta growth mandates.
Technical & Structure Timing Caution: AVDL trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 62.3); meanwhile ANIP is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 41.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on AVDL vs ANIP. Trailing 12-month operating profitability (AVDL 2.5% vs ANIP 14.7%) and valuation multiples (AVDL 28.8x vs ANIP 6.7x Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Drug Manufacturers - Specialty & Generic value chain with $1.6B market capitalization and 14.7% operating margin.
OpEx & R&D Reinvestment46.4% of Rev ($483M)
90D Engineering Disclosures0 Published
Investor FAQ AVDL vs ANIP Key Questions & Quantitative Answers
As of Nov 20, 2026, Avadel Pharmaceuticals plc Ordinary Share (AVDL) captures the overall head-to-head institutional edge over ANI Pharmaceuticals, Inc. (ANIP) on higher Unified Composite conviction (62.9/100 BUY vs. 42.4/100 HOLD) after splitting the core matrix 5–5 (led by Growth & Scale), while ANIP wins 5–1 across the 6-pillar growth and valuation breakdown. AVDL trades at $21.64 (28.8x Forward P/E, 2.5% operating margin) versus ANIP at $68.55 (6.7x Forward P/E, 14.7% operating margin). Growth vs. Quality Trade-Off: AVDL earns the overall head-to-head edge with a stronger Unified Composite Score (62.9/100 BUY vs. ANIP 42.4/100 HOLD) and 0.14β · 2% Vol risk profile, whereas ANIP leads top-line expansion (+27.6% YoY revenue growth, 1.76x PEG, and 5 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: AVDL trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 62.3); meanwhile ANIP is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 41.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
AVDL leads the Growth & Scale pillar: AVDL posts +54.9% YoY revenue growth and +0.0% YoY earnings growth on $249M TTM revenue (94.9% gross margin, 2.5% operating margin), compared with ANIP at +27.6% YoY revenue growth and +33.4% YoY earnings growth on $1.04B TTM revenue (61.1% gross margin, 14.7% operating margin). On trailing 12-month operating scale, AVDL generates $249M in USD-normalized revenue versus $1.04B for ANIP. In operating R&D and SG&A reinvestment, AVDL deploys N/A (0 90-day corporate R&D disclosures) versus 46.4% of Rev ($483M) (0 disclosures) for ANIP.
ANIP screens cheaper on headline valuation multiples. AVDL trades at 28.8x Forward P/E, 16.8x Trailing P/E, 0.07x PEG, and 8.5x EV/Revenue (1.1% EBITDA margin), whereas ANIP trades at 6.7x Forward P/E, 14.0x Trailing P/E, 1.76x PEG, and 1.7x EV/Revenue (19.2% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against AVDL (-0.3% ROE) versus ANIP (20.4% ROE) capital efficiency.
In options market volatility and institutional positioning, AVDL carries 2.4% implied volatility (<1st %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.14β · 2% Vol realized risk). By comparison, ANIP carries 133.6% implied volatility (29th %ile, Balanced (25th–60th %ile)), a 6.40x (Put-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (0.21β · 32% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.